| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d821543cc4e5f7c564c1e9c9a0573159 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-366
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-585
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-685
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-661 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-661 |
| filingDate |
2012-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_20c0736e3fd7000ce34b6d123e3f4506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0600c4bac2dc603f00e58dea761eedab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a943dd34d2790081f21dc11f8157fef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f28104a3eab834f414b39d801f48b957
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e64f150d1759483bfe004387105fb4b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ab250f650651a83299f36fb5c76c130 |
| publicationDate |
2015-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2015320773-A1 |
| titleOfInvention |
Treatment of inflammation |
| abstract |
Disclosed herein are methods of treating an inflammatory disease or disorder, as well as pharmaceutical compositions and kits useful for treating an inflammatory disease or disorder. The methods, compositions and kits utilize at least one agent, the at least one agent being capable of exhibiting at least two activities selected from the group consisting of: a) inhibiting CD 14 activity and/or a signaling pathway associated with CD 14 activity; b) inhibiting TLR2 activity and/or a signaling pathway associated with TLR2 activity; and c) inhibiting monocyte chemotaxis. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10022388-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10464957-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10206936-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113082033-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9771385-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017151687-A1 |
| priorityDate |
2011-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |